Archive for the ‘Bioprocessing’ Category

BREAKING NEWS: BioReliance to Become Part of SAFC

Wednesday, February 1st, 2012

 

Today, Sigma Aldrich confirmed that the newly acquired BioReliance business will become part of SAFC, the custom manufacturing and services business unit of Sigma-Aldrich. SAFC President, Gilles Cottier noted that the acquisition would serve to increase the SAFC value proposition and positively leverage the company’s industrial media presence and biological testing capabilities for end user services and solutions.

(more…)

Hot Off the Press: Sigma-Aldrich to Acquire BioReliance in Order to Extend into Biopharmaceutical Testing and Services

Monday, January 9th, 2012

Today, Sigma-Aldrich Corporation announced plans to acquire BioReliance Holdings for $350M. The acquisition is part of a strategic plan to extend the company’s biopharmaceutical testing and services and increase their value proposition to customers. The extension of these services will allow Sigma-Aldrich to more effectively provide enhanced solutions for its biopharmaceutical customers and also allows customers to work with a single point provider that is more vertically integrated throughout the drug discovery process. The full press release is available by clicking below. Stay tuned to SAFC Live as we provide updates on this new acquisition and what it means for the company and the industry.

(more…)

LIVE from CPhI Worldwide: SAFC Announces Introduction of CHOZN GS Knockout CHO Line

Thursday, October 27th, 2011

Following the introduction of the CHO cell line earlier this year in July, SAFC has just announced the release of a novel CHOZN® GS-/- Zinc Finger Nuclease (ZFN)- modified Chinese Hamster Ovary (CHO) cell line. Designed for use in the production of biopharmaceuticals, the new CHOZN GS-/- cell line is the first commercially available glutamine synthetase (GS) knockout CHO cell line proven to shorten bioproduction times in early development, enabling customers to enhance their speed-to-market and increase cost efficiency. Read more about it on Manufacturing Chemist by clicking here.

Pharma Magazine Feature: From DNA to Harvest: A Platform Approach to Improved Bio-Production

Wednesday, September 28th, 2011

The September/October issue of Pharma Magazine features an article authored by Bruce Lehr, SAFC Director of Development and Kevin Kayser, SAFC Associate Director of Cell Engineering which discusses using a platform development and manufacturing strategy to control operations across biopharmaceutical projects. The article further discusses SAFC’s ZFN (Zinc Finger Nuclease) technology which allows for the isolation of genes for modification. Please take a moment to read the full story here.

Stellar Biotechnologies CEO, Frank Oakes, Discusses KLH Technology and Why They Partnered with SAFC

Tuesday, August 9th, 2011

As promised, we return with a new perspective on the Stellar Biotechnologies and SAFC partnership. On August 3rd, Stellar announced SAFC as a partner for the supply of keyhole limpet hemocyanin (KLH), an important component of several vaccines that are in development. In this segment, Stellar President and Chief Executive Officer, Frank Oakes, explains how it produces KLH, and why the partnership is good for both companies.

(more…)

SAFC to Present at BioProcess International China Conference

Friday, August 5th, 2011

Join SAFC on August 22-23, 2011, at the Grand Hyatt Shanghai for the BioProcess International China Conference. The two-day program, hosted by IBC, is known for bringing together thought leaders and decision makers in biotechnology. SAFC will present on August 22nd as part of a dual track program format, focusing on Cell Culture and Cell Line Development and Product/Process Characterization to Improve Quality and Comparability.

(more…)

“A World of Innovation” – Dr. Sarah Houlton reports for BioProcess International on the SAFC/Sartorius downstream processing day

Tuesday, June 7th, 2011

“The world faces a clear need for innovative biological products to treat and prevent diseases that cause significant health burdens. What might be less obvious is a need for innovation in biomanufacturing processes. If these products are to be made more efficiently and cost-effectively through less wasteful and safer means, then improvements are definitely needed” writes Dr. Sarah Houlton in the excellent report published today in BioProcess International that reviews the Downstream Processing Day co-hosted by SAFC and Sartorius Stedim Biotech and held in Liverpool, UK earlier this year.

(more…)